http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2759998-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed266051d5fbde6af8088f11f42dd6b1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-721 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-721 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06 |
| filingDate | 2018-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e49817b90f4cb961480c33c5b770f4af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24e882407efae527714853f2b2e2a762 |
| publicationDate | 2021-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2759998-C2 |
| titleOfInvention | Glaucoma treatment |
| abstract | FIELD: medicine; ophthalmology.SUBSTANCE: group of inventions relates to the field of medicine, namely ophthalmology; it is intended for the treatment, inhibition or prevention of glaucoma in a subject. Dextran sulfate or its pharmaceutically acceptable salt, having average molecular weight equal to or less than 10,000 Da, is used in the manufacture of a drug for the treatment, inhibition or prevention of glaucoma in a subject. In addition, the specified dextran sulfate or its pharmaceutically acceptable salt is used in the manufacture of a drug for the reduction in intraocular pressure in a subject suffering from glaucoma, in the manufacture of a drug for the treatment, inhibition or prevention of ocular hypertension in a subject, as well as in the manufacture of a drug for the inhibition of the loss of retinal ganglion cells and reduction in a layer of retinal nerve fiber in a subject suffering from glaucoma, preferably open-angle glaucoma and/or ocular hypertension.EFFECT: use of the invention provides for the effective treatment, inhibition or prevention of glaucoma without causing pathological angiogenesis or neovascularization in the eye, as well as a neuroprotective effect to prevent or at least reduce damage and death of retinal ganglion cells and preserve the integrity and thickness of the layer of retinal nerve fiber.22 cl, 11 dwg, 6 tbl, 3 ex |
| priorityDate | 2017-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1025.